Clinical Trial Detail

NCT ID NCT02162719
Title A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Front-line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Genentech
Indications

triple-receptor negative breast cancer

Therapies

Ipatasertib + Paclitaxel

Paclitaxel

Age Groups: adult

Additional content available in CKB BOOST